Want to see NGNE full AI Analyst Report?
Top Page
Neurogene
(NASDAQ:NGNE)
Select Model
Select Model
Rating:49Neutral
Price Target:
$30.00
▼(-26.54% Downside)
Action:Reiterated
Date:10/29/26
The score is weighed down primarily by weak financial performance (no meaningful revenue, widening losses, and rising cash burn), which raises ongoing financing/runway risk despite low leverage. Technicals are mixed (better than the 20-day and 200-day trends but still below the 50/100-day with a negative MACD). Valuation is also a headwind because negative earnings make P/E less meaningful and no dividend support is indicated.
Positive Factors
Differentiated NGN-401 gene therapy design
NGN-401’s ability to deliver the full-length MECP2 gene while regulating expression on a cell-by-cell basis could provide a meaningful product distinction in Rett syndrome. The reported preclinical expression and durability findings support continued clinical development and potential therapeutic differentiation.
Negative Factors
Pre-revenue profile and widening losses
The absence of meaningful revenue leaves Neurogene dependent on clinical progress and external capital rather than internally generated operating income. Widening losses and persistently negative gross profit indicate that development spending is not yet being offset by commercialization, increasing execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Differentiated NGN-401 gene therapy design
NGN-401’s ability to deliver the full-length MECP2 gene while regulating expression on a cell-by-cell basis could provide a meaningful product distinction in Rett syndrome. The reported preclinical expression and durability findings support continued clinical development and potential therapeutic differentiation.
Read all positive factors
Neurogene (NGNE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$551.31M
Dividend YieldN/A
Average Volume (3M)387.30K
Price to Earnings (P/E)―
Beta (1Y)3.11
Revenue GrowthN/A
EPS Growth-18.84%
CountryUS
Employees131
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.51
Shares Outstanding20,011,381
10 Day Avg. Volume378,556
30 Day Avg. Volume387,296
Financial Highlights & Ratios
PEG Ratio5.20
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-5.57
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-26.07
Enterprise Value/Ebitda-4.56
Forecast
1Y Price Target
$80.17Price Target Upside96.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-5.64
Revenue Forecast (FY)N/A
Neurogene Business Overview & Revenue Model
Company Description
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-4...
Neurogene Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
68
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 925.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -18.88M | -3.19M | -2.32M | -3.26M | -3.20M | -42.26M |
| EBITDA | -107.88M | -87.25M | -71.89M | -33.01M | -51.99M | -49.57M |
| Net Income | -111.11M | -90.35M | -75.14M | -36.32M | -55.19M | -50.52M |
Balance Sheet | ||||||
| Total Assets | 244.36M | 288.60M | 335.73M | 222.57M | 109.27M | 101.49M |
| Cash, Cash Equivalents and Short-Term Investments | 225.39M | 269.01M | 312.40M | 197.16M | 82.02M | 70.54M |
| Total Debt | 8.35M | 9.89M | 12.43M | 16.25M | 4.69M | 6.43M |
| Total Liabilities | 27.23M | 23.72M | 25.36M | 36.55M | 10.64M | 193.36M |
| Stockholders Equity | 217.13M | 264.89M | 310.38M | 186.02M | 98.63M | -91.88M |
Cash Flow | ||||||
| Free Cash Flow | -87.11M | -78.36M | -71.41M | -51.74M | -55.05M | -64.77M |
| Operating Cash Flow | -86.24M | -77.17M | -70.60M | -51.42M | -52.82M | -46.40M |
| Investing Cash Flow | 104.66M | 14.00M | -125.26M | 25.64M | -2.23M | -18.37M |
| Financing Cash Flow | 36.61M | 30.43M | 184.07M | 92.48M | 66.53M | 51.06M |
Neurogene Technical Analysis
Positive
40.84
Price Trends
30.73
Negative
32.68
Negative
27.82
Negative
Market Momentum
-0.65
Negative
50.97
Neutral
68.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NGNE, the sentiment is Positive. The current price of 40.84 is above the 20-day moving average (MA) of 25.34, above the 50-day MA of 30.73, and above the 200-day MA of 27.82, indicating a neutral trend. The MACD of -0.65 indicates Negative momentum. The RSI at 50.97 is Neutral, neither overbought nor oversold. The STOCH value of 68.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NGNE.
Neurogene Risk Analysis
Neurogene disclosed 88 risk factors in its most recent earnings report. Neurogene reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Neurogene Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $657.41M | -4.38 | -41.33% | ― | 278712.12% | 26.59% | |
49 Neutral | $551.31M | -5.00 | -45.11% | ― | ― | -18.84% | |
49 Neutral | $708.05M | -3.36 | -44.48% | ― | -35.07% | -45.17% | |
48 Neutral | $257.76M | -2.73 | -41.85% | ― | ― | 64.51% | |
44 Neutral | $475.29M | -1.90 | -220.07% | ― | 12.00% | -9.21% | |
41 Neutral | $664.80M | -3.25 | -72.28% | ― | ― | 31.81% |
* Healthcare Sector Average
NGNE
Neurogene
27.55
-6.71
-19.59%
RGNX
RegenXBio
7.20
-5.57
-43.62%
WVE
Wave Life Sciences
3.59
-5.45
-60.29%
SLDB
Solid Biosciences
6.20
0.81
15.03%
FDMT
4D Molecular Therapeutics
11.90
0.40
3.48%
LXEO
Lexeo Therapeutics, Inc.
3.14
-6.87
-68.63%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.